http://www.who.int/tb/challenges/ltbi_faqs/en/ Latent TB infection (LTBI) is a condition in which TB bacteria (M. tuberculosis) survive in the body in a dormant state.
National Institute for Health and Care Excellence (NICE)
(https://www.nice.org.uk/guidance/ng33/resources/tuberculosis-pdf-1837390683589) Latent TB The initial infection clears in over 80% of people but, in a few cases, a defensive barrier is built round the infection and the TB bacteria lie dormant. This is called latent TB; the person is not ill and is not infectious.
Supplementary box 2-Funding for TB latency

NIH RFA
Title "Response to the Presidential Vaccine Initiative -Overcoming the Tuberculosis Latency Challenge" (https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-01-009.html)
Wording of call "The objective of this Request for Applications (RFA) is to stimulate investigatorinitiated research to elucidate the mechanisms underlying persistent, asymptomatic infection (also referred to as "latency") with Mycobacterium tuberculosis. … A better understanding of persistent infection is an essential step toward developing improved intervention strategies to eliminate tuberculosis as a public health problem."
2005 BMGF Grand Challenge in Global Health, a family of initiatives fostering innovation to solve key global health and development problems (https://gcgh.grandchallenges.org/)
One of the 43 funded grants was entitled "Drugs for treatment of latent tuberculosis" with the following abstract: An estimated 2 billion individuals-a third of the world's population-have been exposed to Mycobacterium tuberculosis (MTB) and carry the infection in its latent form, retaining a lifelong risk of developing TB disease. Programs to control tuberculosis now focus on childhood vaccination and treatment for people with active disease. Reversing TB's spread, however, requires an intervention that will prevent disease in those who are already infected. The lack of knowledge about the biology of latent TB infection stands in the way of the development of such an intervention. [An] international team of researchers from the U.K., U.S., Singapore, Korea, and Mexico is attempting to further elucidate the fundamental biology of latency and use this knowledge to develop drugs against latent TB.
2008 BMGF Grand Challenges Explorations (https://gcgh.grandchallenges.org/challenge/explorebasis-latency-tuberculosis-round-1 and https://gcgh.grandchallenges.org/challenge/explore-basislatency-tuberculosis-round-2).
Call for LTBI proposals: " ROADBLOCK: Most humans exposed to Mycobacterium tuberculosis contain the infection in an asymptomatic latent form. One third of the world's population is estimated to have latent TB, representing a vast reservoir from which active disease and subsequent transmission propagates. Interventions that identify and eliminate latent infection might break the cycle of disease transmission and reverse the TB epidemic."
Of the 1313 awards made, 15 were to study TB latency (https://gcgh.grandchallenges.org/grants?f[0]=field_challenge%253Afield_initiative%3A37073&f[1] =field_challenge%253Afield_short_title%3ATuberculosis%20Latency)
